We are live on ! Find out more
HRMY icon

Harmony Biosciences

273 hedge funds and large institutions have $1.65B invested in Harmony Biosciences in 2025 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 98 increasing their positions, 88 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $4.94M | Put options by funds: $1.57M

147% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 17

11% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 88

10% more funds holding

Funds holding: 248 → 273 (+25)

5.67% less ownership

Funds ownership: 92.5% → 86.84% (-5.7%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

41% less capital inflows, than outflows

Capital inflows: $149M | Capital outflows: $252M

Holders
273
Holders Change
+25
Holders Change %
+10.08%
% of All Funds
3.64%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
42
Increased
98
Reduced
88
Closed
17
Calls
$4.94​M
Puts
$1.57​M
Net Calls
+$3.38​M
Net Calls Change
+$889​K

HRMY Hedge Fund Activity: Q1 2025 in Review

273 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2025, worth a combined $1.65B — down 8.9% from $1.82B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new HRMY positions and 17 closed out — a net gain of 25 holders — while 98 added to existing stakes and 88 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $9.7M. The largest seller was Pacer Advisors, cutting an estimated $63.9M.

  • 273 institutional investors held Harmony Biosciences (HRMY) as of Q1 2025, up from 248 in Q4 2024.
  • Funds reported $1.65B of Harmony Biosciences stock for Q1 2025, down 8.9% quarter-over-quarter.
  • 42 funds opened new Harmony Biosciences positions in Q1 2025 and 17 closed out, a net change of +25 holders.
  • The largest Harmony Biosciences buyer in Q1 2025 was Renaissance Technologies, an estimated $9.7M added.
  • The largest Harmony Biosciences seller in Q1 2025 was Pacer Advisors, an estimated $63.9M sold.

Based on aggregated 13F filings for Q1 2025.